DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Refractory Multiple Myeloma Pipeline Report to explore emerging therapies, key Refractory Multiple Myeloma Companies, and future Refractory Multiple Myeloma treatment landscapes @ Refractory Multiple Myeloma Pipeline Outlook Report
Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
- In July 2025, Sanofi announced a study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
- In July 2025, Janssen Research & Development LLC conducted a study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
- In July 2025, Gracell Biotechnologies (Shanghai) Co., Ltd. organized a study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.Eligible subjects will be performed a leukapheresis procedure to manufacture GC012F. Subjects will receive a single dose of GC012F infusion at specified dose levels, after three consecutive days of lymphodepletion consisting of fludarabine and cyclophosphamide. Bridging therapy is allowed between leukapheresis and lymphodepletion.
- In July 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).
- In July 2025, Sanofi conducted a study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy, and to characterize the PK of isatuximab in combination with carfilzomib and dexamethasone after manual and On Body Delivery System (OBDS) administration. After confirmation of the feasibility of SC isatuximab by manual administration, patient will be randomized to 1 of the 2 delivery methods of SC isatuximab.
- In July 2025, Kite, A Gilead Company conducted a Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
- In July 2025, AstraZeneca organized a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM. This study will follow a modular protocol design evaluating AZD0305 as monotherapy and in combination with other anticancer agents.
- DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Refractory Multiple Myeloma treatment.
- The leading Refractory Multiple Myeloma Companies such as MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
- Promising Refractory Multiple Myeloma Pipleline Therapies such as Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.
Stay ahead with the most recent pipeline outlook for Refractory Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Refractory Multiple Myeloma Treatment Drugs
Refractory Multiple Myeloma Emerging Drugs Profile
- Felzartamab: MorphoSys
Felzartamab is an investigational human monoclonal antibody developed using MorphoSys' HuCAL® antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.
- RAPA-201: Rapa Therapeutics
RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.
- PHE885: Novartis
PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.
- ABBV 453: AbbVie
ABBV-453 is an investigational drug candidate being developed for the treatment of relapsed or refractory multiple myeloma. It is administered through oral route as tablet formulation. It acts by targeting B-cell lymphoma 2 (BCL-2) protein. Currently the drug is in Phase I stage of clinical trials.
The Refractory Multiple Myeloma Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Multiple Myeloma treatment.
- Refractory Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Multiple Myeloma market.
Explore groundbreaking therapies and clinical trials in the Refractory Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New Refractory Multiple Myeloma Drugs
Refractory Multiple Myeloma Companies
MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Refractory Multiple Myeloma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Unveil the future of Refractory Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Refractory Multiple Myeloma Market Drivers and Barriers
Scope of the Refractory Multiple Myeloma Pipeline Report
- Coverage- Global
- Refractory Multiple Myeloma Companies- MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
- Refractory Multiple Myeloma Pipleline Therapies- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.
- Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Refractory Multiple Myeloma Drug development? Find out in DelveInsight’s exclusive Refractory Multiple Myeloma Pipeline Report—access it now! @ Refractory Multiple Myeloma Emerging Drugs and Major Companies
Table of Contents
- Introduction
- Executive Summary
- Multiple Myeloma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Comparative Analysis
- Felzartamab: MorphoSys
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RAPA-201: Rapa Therapeutics
- Early Stage Products (Phase I )
- Comparative Analysis
- ABBV 453: AbbVie
- Inactive Products
- Refractory Multiple Myeloma Key Companies
- Refractory Multiple Myeloma Key Products
- Refractory Multiple Myeloma- Unmet Needs
- Refractory Multiple Myeloma- Market Drivers and Barriers
- Refractory Multiple Myeloma- Future Perspectives and Conclusion
- Refractory Multiple Myeloma Analyst Views
- Refractory Multiple Myeloma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight
